TransMedics Group, Inc. (NASDAQ:TMDX) Stock Position Reduced by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating) by 21.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 28,232 shares of the company’s stock after selling 7,927 shares during the quarter. Envestnet Asset Management Inc. owned 0.09% of TransMedics Group worth $1,742,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Oakworth Capital Inc. purchased a new stake in shares of TransMedics Group during the fourth quarter worth $25,000. MinichMacGregor Wealth Management LLC purchased a new stake in shares of TransMedics Group during the 4th quarter worth about $42,000. MCF Advisors LLC acquired a new stake in shares of TransMedics Group during the 3rd quarter valued at about $43,000. Royal Bank of Canada grew its stake in shares of TransMedics Group by 643.0% in the 3rd quarter. Royal Bank of Canada now owns 1,122 shares of the company’s stock valued at $46,000 after buying an additional 971 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of TransMedics Group by 125.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,603 shares of the company’s stock valued at $109,000 after buying an additional 1,448 shares in the last quarter. Hedge funds and other institutional investors own 88.58% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Waleed H. Hassanein sold 37,827 shares of the company’s stock in a transaction dated Thursday, February 23rd. The shares were sold at an average price of $73.65, for a total transaction of $2,785,958.55. Following the completion of the transaction, the chief executive officer now owns 388,617 shares of the company’s stock, valued at $28,621,642.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 37,827 shares of the business’s stock in a transaction dated Thursday, February 23rd. The stock was sold at an average price of $73.65, for a total transaction of $2,785,958.55. Following the transaction, the chief executive officer now directly owns 388,617 shares in the company, valued at $28,621,642.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 35,930 shares of the company’s stock in a transaction that occurred on Thursday, February 23rd. The shares were sold at an average price of $73.51, for a total value of $2,641,214.30. Following the completion of the transaction, the insider now directly owns 14,375 shares of the company’s stock, valued at approximately $1,056,706.25. The disclosure for this sale can be found here. Insiders have sold 140,217 shares of company stock worth $10,737,180 in the last ninety days. Insiders own 6.70% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $72.44 on Monday. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -76.25 and a beta of 1.44. The business has a 50 day moving average price of $75.02 and a 200 day moving average price of $67.06. The company has a quick ratio of 8.30, a current ratio of 9.14 and a debt-to-equity ratio of 0.31. TransMedics Group, Inc. has a twelve month low of $24.01 and a twelve month high of $90.15.

TransMedics Group (NASDAQ:TMDX – Get Rating) last posted its quarterly earnings data on Monday, May 1st. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.17. TransMedics Group had a negative return on equity of 18.30% and a negative net margin of 23.76%. The company had revenue of $41.60 million during the quarter, compared to analysts’ expectations of $36.05 million. During the same period in the prior year, the business earned ($0.38) earnings per share. TransMedics Group’s revenue for the quarter was up 161.6% compared to the same quarter last year. Research analysts predict that TransMedics Group, Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

TMDX has been the subject of a number of analyst reports. Cowen lifted their target price on shares of TransMedics Group from $70.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, February 23rd. Canaccord Genuity Group raised their target price on TransMedics Group from $68.00 to $78.00 and gave the company a “buy” rating in a report on Thursday, February 23rd. Oppenheimer boosted their price target on TransMedics Group from $85.00 to $90.00 in a research report on Tuesday, May 2nd. JPMorgan Chase & Co. increased their price objective on TransMedics Group from $67.00 to $81.00 and gave the company an “overweight” rating in a report on Thursday, February 23rd. Finally, Morgan Stanley boosted their target price on TransMedics Group from $63.00 to $74.00 and gave the stock an “equal weight” rating in a report on Thursday, February 23rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.29.

About TransMedics Group

(Get Rating)

TransMedics Group, Inc operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.